MYD88 and melanoma: Consistent with our screening results, inhibition of IGF1R,30, 31, 32, 33, 34, 35, 36 JAK137, 38 and ACVR1 (also known as ALK2)39, 40, 41 have been shown to inhibit PCa cell growth and progression, particularly in hormone‐refractory PCa; while MAPK2 and IRAK4 have been implicated in tumorigenesis in other cancers including colorectal cancer,42, 43 breast cancer,44 pancreatic ductal adenocarcinoma,45 chronic lymphocytic leukaemia cells,46, 47 mutant MYD88 L265P diffuse large B cell lymphoma48, 49, 50, 51 and melanoma.52